

Hepatitis C Virus Test

(Colloidal Gold)

Diagnostic Sensitivity and Specificity Study Report

Final report date: 2016-06-20

Table of Contents

Title Page

Table of Contents

Study Director Signature and Verification Dates

Study Summary

1. Purpose
2. Reference and Compliance
3. Materials
4. Study Design
5. Evaluation Criteria
6. Result
7. Conclusion
8. Report

Study Director Signature and Verification Dates

This study meets with the technical requirements of the protocol. The study also meets with technical specification for the test.

Study Director: Zhao Liwei

Company: Atlas Link (Beijing) Technology Co., Ltd

Position: Head of R & D Department

Verification Dates:2016-06-20

Study Summary

The purpose of this study was to obtain accurate information about the diagnostic sensitivity and specificity of the Hepatitis C Virus Test (Colloidal Gold), and we have evaluated the clinical effects of the Hepatitis C Virus Test (Colloidal Gold). The clinical evaluation was carried out for the clinical performance of Hepatitis C Virus Test (Colloidal Gold). Total 2138 samples were tested, of which the diagnostic sensitivity is 99.76%; diagnostic specificity is 99.59%; total compliance is 99.63%.

1. Purpose

To validate the diagnostic sensitivity and specificity of Hepatitis C Virus Test (Colloidal Gold).

2. Reference and Compliance

FDA guidance for In vitro diagnostic medical device

SFDA guidance

The present study conformed to all applicable laws and regulations.

3. Reagent and Materials

- Hepatitis C Virus Test (Colloidal Gold), Lot No.: HCV-1.
- CE Marked Ortho HCV 3.0 EIATest, LOT: 20160502
- Patient samples collected by

Evaluation Site	Negative sample	Positive sample
PLA 302 Hospital	200 hospitalized patients	10 Commercial HCV seroconversion Panels(BBI and ZMC)
	200 pregnant women	
Key Laboratory of Molecular Biology on Infectious Diseases, Chongqing University of Medical Sciences	146 specimens from patients of potential interference diseases	20 public HCV seroconversion Panels
Sichuan Center for Disease Control and Prevention	90 specimens from patients of potential interference diseases	267 HCV positive serum or plasma samples including 94 specimens known HCV genotype
Key Laboratory of Molecular Biology on Infectious Diseases, Chongqing University of Medical Sciences	472 specimens from blood donors	144 HCV positive serum or plasma samples including 81 specimens known HCV genotype
Blood Center of Beijing Red Cross Society	619 specimens from blood donors	N/A

4. Study Design:

4.1 Making evaluation for patient samples.

- Subject was a patient admitted to the hospital due to a respiratory virus infection;
- Total about 1727 negative samples and 411 positive samples were collected;

4.2 Examiner and clinical laboratories

- PLA 302 Hospital
- Key Laboratory of Molecular Biology on Infectious Diseases, Chongqing University of Medical Sciences
- Sichuan Center for Disease Control and Prevention

4.3 Sample requirement:

All the samples were confirmed.

Samples were to be randomly chosen and double-black labeled.

4.4 Test conduction:

- All tests were performed by the clinical technicians in each clinical laboratory according to the

manufacturer's instructions using the confirmed samples.

- Visual interpretations of the results of Hepatitis C Virus Test were made independently by the clinical technician.
- The testing center was responsible to summarize the result and send to Atlas Link

5. Evaluation Criteria

Positive(+): Both C and T lines appear regardless of color intensity.

Negative(-) : Only C line appears.

Undeterminable ($\pm$): C line appears; T line is so weak that it cannot be determined as positive.

Invalid result(/): Neither C line nor T line appears.

6. Results

Total 30 seroconversion panels including 20 from public source and 10 from commercial source were used to determine the relative diagnostic sensitivity of Hepatitis C Virus Test. The relative diagnostic sensitivity was determined by comparing the earliest detection date of serum conversion of the patient to HCV seropositive with the HCV serological status of each series bleed with that of CE-market HCV product or with the data provided by BBI or ZMC. For the 20 seroconversion panels from public source, Hepatitis C Virus Test showed earlier detection of seroconversion on panel HCV-989 than CE approved Ortho HCV 3.0, the value was -1. Later detection of seroconversion on panel HCV-041 than Ortho 's HCV products, the values was -1. Compared the relative diagnostic sensitivity of Hepatitis C Virus Test with that of Ortho HCV 3.0 EIA on HCV seroconversion panels, The total value was 0 (Table 2). For the 10 commercial seroconversion panels, Hepatitis C Virus Test showed earlier detection of seroconversion on panel HCV6228 than Abbot's products, the value was -1. Earlier detection of seroconversion on panel PHV913 and HCV6224 than Ortho 's HCV products, the values were -2 and -2 respectively; later detection of seroconversion on panel PHV919, the value was +1, the total value was -3 (Table 3).

Table 2 Summary of Seroconversion Panels (Public Source) Detection at Hepatitis C Virus Test

Panel Code	Period of Detection from the First Bleed Day		
	Ortho HCV 2.0/3.0	Hepatitis C Virus Test	Hepatitis C Virus Test results value compared with Ortho 3.0
HCV-973	10	10	0
HCV-976	10	10	0
HCV-982	41	41	0
HCV-983	20	20	0
HCV-986	41	41	0
HCV-989	6	3	-1
HCV-991	4	4	0
HCV-011	27	27	0
HCV-012	24	24	0
HCV-032	14	14	0
HCV-033	16	16	0
HCV-041	19	39	+1

HCV-042	27	27	0
HCV-043	29	29	0
HCV-072	11	11	0
HCV-074	14	14	0
HCV-081	15	15	0
HCV-102	4	4	0
HCV-103	9	9	0
HCV-111	7	7	0

Table 3 Summary of Seroconversion Panels (Commercial Source) Detection at Hepatitis C
Virus Test

Panel Code	Period of Detection from the First Bleed Day			
	Abbot HCV 2.0/4.0 EIA	Ortho HCV 2.0/3.0	Hepatitis C Virus Test	Hepatitis C Virus Test results value compared with Abbot /Orhto
PHV911	13	13	13	0/0
PHV913	7	Not detected	7	0/-2
PHV919	32	28	32	0/+1
HCV6213	43	43	43	0/0
HCV6215	20	20	20	0/0
HCV6224	23	Not detected	23	0/-2
HCV6226	39	39	9	0/0
HCV6227	74	74	74	0/0
HCV6228	36	31	31	-1/0
HCV6241	61	61	61	0/0

Total 411 positive serum samples including 6 genotypes (Among the 411 specimens, there were 267 from SCCDC and 144 from Chongqing Medical University) were selected to evaluate the diagnostic sensitivity of Hepatitis C Virus Test and compare the results with CE marked Ortho HCV 3.0 EIA. From study results of SCCDC (Table 4), 267 positive samples were tested 267 positive by both Hepatitis C Virus Test and Ortho HCV 3.0. The diagnostic sensitivity of Hepatitis C Virus Test was 100% (267/267). From study results of Chongqing Medical University (Table 5), 143 of 144 HCV positive sera were tested positive by Hepatitis C Virus Test, the negative one tested by Hepatitis C Virus Test showed positive by Ortho HCV EIA. The sensitivity of Hepatitis C Virus Test was 99.31% (143/144). All the samples with known genotype 1-6 were tested as positive by both assays. Total 411 positive samples were tested 410 positive, 1 tested negative by Hepatitis C Virus Test which showed inconsistent results with CE marked Ortho HCV 3.0 EIA and was further confirmed positive by PCR. The genotype of the false negative sample was unknown. The diagnostic sensitivity of Hepatitis C Virus Test was 99.76% (410/411) and could identify HCV genotype 1-6.

Table 4 Summary of HCV positive specimens' detection from SCCDC at Hepatitis C Virus Test

Atlas Link (Beijing) Technology Co., Ltd

Room 811 Zeyang Plaza, No.166 Fushi Road,

Shijingshan Dist. Beijing 100043, China

Website: <https://www.invitro-test.com>

Doc No. ALK-CE-HCV- APPENDIX 5

Version No. A1

Page 8 of 12

Genotype		Results of Hepatitis C Virus Test		Results of CE Marked Test		Subtotal
		Positive	Negative	Positive	Negative	
1	1a	2	0	2	0	23
	1b	21	0	21	0	
2	2a	10	0	10	0	18
	2b	5	0	5	0	
	2a/2b	3	0	3	0	
3	3a	8	0	8	0	15
	3b	7	0	7	0	
4	4	5	0	5	0	16
	4a	5	0	5	0	
	4c/4d	6	0	6	0	
5a		4	0	4	0	4
6	6a	12	0	12	0	16
	6e	4	0	4	0	
1b/2a		2	0	2	0	2
Unknown genotype		173	0	173	0	173
Subtotal		267	0	267	0	267

Table 5 Summary of HCV Positive Specimens' Detection from Chongqing Medical University at Hepatitis C

Virus Test

Genotype		Results of Hepatitis C Virus Test		Results of Ortho HCV EIA		Subtotal
		Positive	Negative	Positive	Negative	
1	1a	2	0	2	0	28
	1b	26	0	26	0	
2	2a	15	0	15	0	19
	2b	4	0	4	0	
3	3a	9	0	9	0	13
	3b	4	0	4	0	
4	4	2	0	2	0	4
	4a	2	0	2	0	
5a		2	0	2	0	2
6	6a	10	0	10	0	14
	6e	4	0	4	0	
1b/2a		1	0	1	0	1
Unknown genotype		62	1	63	0	63
Subtotal		143	1	144	0	144

Table 6 Summary of HCV Positive Specimens' Detection at Hepatitis C Virus Test

Genotype		Results of Hepatitis C Virus Test		Results of CE Marked Test		Subtotal
		Positive	Negative	Positive	Negative	
1	1a	4	0	4	0	51
	1b	47	0	47	0	
2	2a	25	0	25	0	37
	2b	9	0	9	0	

Atlas Link (Beijing) Technology Co., Ltd

Room 811 Zeyang Plaza, No.166 Fushi Road,

Shijingshan Dist. Beijing 100043, China

Website: <https://www.invitro-test.com>

Doc No. ALK-CE-HCV- APPENDIX 5

Version No. A1

Page 9 of 12

	2a/2b	3	0	3	0	
3	3a	17	0	17	0	28
	3b	11	0	11	0	
4	4	7	0	7	0	20
	4a	7	0	7	0	
	4c/4d	6	0	6	0	
5a		7	0	7	0	7
6	6a	22	0	22	0	30
	6e	8	0	8	0	
1b/2a		3	0	3	0	3
Unknown genotype		234	1	235	0	235
Subtotal		410	1	411	0	411

Total 200 specimens with known un-HCV positive from hospitalized patients in PLA 302 Hospital, PRC, were used to evaluate the diagnostic specificity among inpatients. 200 of 200 specimens were tested anti-HCV negative by both Hepatitis C Virus Test and Ortho HCV 3.0 EIA. The diagnostic specificity of Hepatitis C Virus Test in inpatients was 100% (200/200). (Table 7)

Table 7 Summary of Diagnostic Specificity of Hepatitis C Virus Test among Inpatients

200 inpatients	Results of Hepatitis C Virus Test		Results of Ortho HCV 3.0 EIA		Subtotal
	Negative	Positive	Negative	Positive	
True Negative	200	0	200	0	200
True Positive	0	0	0	0	0
Subtotal	200	0	200	0	200

Among the 200 pregnant women, there were 10 multiparas. 199 of 200 specimens were tested anti-HCV negative by Hepatitis C Virus Test and Ortho HCV 3.0 EIA. The reactive samples were tested repeatedly by these two Tests. 2 specimens showed disagreement results between Hepatitis C Virus Test and Ortho. Result from Hepatitis C Virus Test was negative while that from Ortho was positive at sample No. 22; Result from Nova was positive while that from Ortho was negative at sample No. 181. Further Real-time PCR (COBAS® AmpliPrep/COBAS® TaqMan® HCV Test, Roche Molecular Systems, Inc) was carried out at these two samples. PCR showed negative results with both samples. The diagnostic specificity of Hepatitis C Virus Test in pregnant women was 99.5% (199/200). (Table 8)

Table 8 Summary of Diagnostic Specificity of Hepatitis C Virus Test among Pregnant Women

200 Pregnant Women	Results of Hepatitis C Virus Test		Results of Ortho HCV 3.0 EIA		Subtotal
	Negative	Positive	Negative	Positive	
True Negative	199	1	199	1	200
True Positive	0	0	0	0	0
Subtotal	199	1	199	1	200

Total 236 specimens (146 from Chongqing Medical University and 90 from SCCDC) from patients with potential interference diseases were tested to evaluate the diagnostic specificity of Hepatitis C Virus Test. The potential interference diseases status were HAV, HBV, HIV, Dengue, EBV, CMV, HTLV, Rubella and E.coli infections, CRF, ASOT, RF positive. There were at least 15 specimens for each interference status. 146 specimens from Chongqing Medical University included the interference status of HAV, HBV, HIV, EBV, RF, CMV, ASOT, CRF, Dengue, Rubella and HTLV positive. These 146 specimens had no interference with Hepatitis C Virus Test (Table 9). 90 specimens from SCCDC included the interference status of HAV, HIV Dengue, HTLV and E.coli positive. 89 of the 90 specimens showed negative results by Hepatitis C Virus Test. The one tested as false positive by Nova is Anti-E.coli positive serum No. 89 (Table 10). Among the 236 interference specimens, 235 showed no interference with Hepatitis C Virus Test. The diagnostic specificity among potential interference disease status was 99.58%(235/236)(Table 11)

Table 9 Summary of Diagnostic Specificity of Hepatitis C Virus Test among Interference Disease Status(Chongqing Medical University)

Interference Diseases	Results of Hepatitis C Virus Test		Results of CE Marked Ortho HCV 3.0 Test		Subtotal
	Positive	Negative	Positive	Negative	
HAV	0	12	0	12	12
HBV	0	20	0	20	20
HIV	0	15	0	15	15
Dengue	0	5	1	4	5
CMV	0	15	0	15	15
EBV	0	15	0	15	15
HTLV	0	4	0	4	4
Rubella	0	15	0	15	15
RF	0	15	0	15	15
CRF	0	15	0	15	15
ASOT	0	15	0	15	15
Subtotal	0	146	1	146	146

Table 10 Summary of Diagnostic Specificity of Hepatitis C Virus Test among interference Disease Status(SCCDC)

Interference Diseases	Results of Hepatitis C Virus Test		Results of CE Marked Ortho HCV 3.0 Test		Subtotal
	Positive	Negative	Positive	Negative	
HAV	0	20	0	20	20
HIV	0	20	0	20	20
Dengue	0	16	1	15	16
HTLV	0	13	0	13	13
E.coli	1	20	0	21	21
Subtotal	1	89	1	89	90

Table 11 Summary of Diagnostic Specificity of Hepatitis C Virus Test among Interference Disease Status

Interference Diseases	Results of Hepatitis C Virus Test		Results of CE Marked Ortho HCV 3.0 Test		Subtotal
	Positive	Negative	Positive	Negative	
HAV	0	32	0	32	32

HBV	0	20	0	20	20
HIV	0	35	0	35	35
Dengue	0	21	1	20	21
CMV	0	15	0	15	15
EBV	0	15	0	15	15
HTLV	0	17	0	17	17
Rubella	0	15	0	15	15
RF	0	15	0	15	15
CRF	0	15	0	15	15
ASOT	0	15	0	15	15
E.Coli	1	20	0	21	21
Subtotal	1	235	1	235	236

Total 1091 specimens from blood donors (619 from Blood Center of Beijing Red Cross Society and 472 from Blood Transfusion Department, the Secondary Affiliated Hospital of Chongqing Medical University) were used to evaluate the diagnostic specificity of Hepatitis C Virus Test. The 1091 specimens consisted of 83 specimens from consecutive blood donations. Among the 619 specimens from Blood Center of Beijing Red Cross Society, 616 showed negative results by Hepatitis C Virus Test, the diagnostic specificity was 99.52% (Table 12). Among the 472 specimens from Chongqing Medical University, 470 showed negative results by Hepatitis C Virus Test, the diagnostic specificity was 99.58%(Table 13). Combined these two results together, total 1091 specimens from blood donors, 1086 showed negative results by Hepatitis C Virus Test, 5 gave false positive; the diagnostic specificity among blood donors was 99.54%(Table 14)

Table 12 Summary of Diagnostic Specificity of Hepatitis C Virus Test among Blood Donors (Blood Center of Beijing Red Cross Society)

Blood donors	Results of Hepatitis C Virus Test		Results of Ortho HCV 3.0 EIA		Subtotal
	Negative	Positive	Negative	Positive	
True Negative	616	3	618	1	619
True Positive	0	0	0	0	0
Subtotal	616	3	618	1	619

Table 13 Summary of Diagnostic Specificity of Hepatitis C Virus Test among Blood Donors (Chongqing Medical University)

Blood donors	Results of Hepatitis C Virus Test		Results of Ortho HCV 3.0 EIA		Subtotal
	Negative	Positive	Negative	Positive	
True Negative	470	2	471	1	472
True Positive	0	0	0	0	0
Subtotal	470	2	471	1	472

Table 14 Summary of Diagnostic Specificity of Hepatitis C Virus Test among Blood Donors

Blood donors	Results of Hepatitis C Virus Test		Results of Ortho HCV 3.0 EIA		Subtotal
	Negative	Positive	Negative	Positive	
True Negative	1086	5	1089	2	1091
True Positive	0	0	0	0	0
Subtotal	1086	5	1089	2	1091

From the 6 diagnostic specificity studies among different populations, total 1727 negative samples including 1091 from blood donors, 200 from inpatients, 200 from pregnant women, 236 from potentially interfering diseases were selected to evaluate the specificity of Hepatitis C Virus Test and Compare the results with CE marked Ortho HCV 3.0. Of the 1727 samples, 1720 were tested negative, 7 tested positive(5 from blood donors, 1 from potentially interfering diseases, 1 from pregnant women) by Hepatitis C Virus Test. All the results which showed inconsistent with CE marked Ortho HCV 3.0 were further confirmed negative by PCR. The diagnostic sensitivity of Hepatitis C Virus Test was 99.59% (1720/1727), false positive rate is 0.41% (Table 15).

Table 15 Summary of Diagnostic Specificity of Hepatitis C Virus Test

	Results of Hepatitis C Virus Test		Results of CE Marked Ortho HCV 3.0 EIATest		Subtotal
	Negative	Positive	Negative	Positive	
Blood Donors	1086	5	1089	2	1091
200 clinic al specimens	200	0	200	0	200
200 Pregnant Women	199	1	199	1	200
236 potentially interfering samples	235	1	235	1	236
Subtotal	1720	7	1723	4	1727

Table 16 Summary of all data

		Hepatitis C Virus Test (Colloidal Gold)		Total
		POS	NEG	
HCV Samples	POS	410	1	411
	NEG	7	1720	1727
Total		417	1721	2138

Diagnostic Sensitivity: $410/411 \times 100\% = 99.76\%$

Diagnostic Specificity: $1720/1727 \times 100\% = 99.59\%$

Overall Agreement: $(410+1720)/2138 \times 100\% = 99.63\%$

7. Conclusion

The clinical evaluation was carried out for the clinical performance of Hepatitis C Virus Test (Colloidal Gold). Total 2138 samples were tested, of which the diagnostic sensitivity is 99.76%; diagnostic specificity is 99.59%; total compliance is 99.63%.

8. Report

8.1 Original raw data is archived at Quality Control Department

8.2 The original final report is archived in Quality Control Department.